Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, announced it has raised additional funding at a $1.8 billion valuation, marking significant investor confidence in the anti-aging research space.
The landmark trial between Elon Musk and OpenAI entered its second week with OpenAI firing back at Musk's allegations. Shivon Zilis revealed that Musk attempted to poach Sam Altman, raising questions about Musk's motivations for bringing the lawsuit.
Elon Musk left OpenAI's board in February 2018 following rejection of his proposal to run the AI research organization he co-founded. The departure marked a significant split between Musk and Sam Altman over the direction of the company.
